Market Research Report

A quick peek into the report

Global Viral and Non-Viral Vector Manufacturing Market

Focus on Vector Type, Application, Disease and Region - Analysis and Forecast, 2021-2031

 
Some Faq's

Frequently Asked Questions

The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.
The top market players are Boehringer Ingelheim, Catalent, Inc., FUJIFILM Holdings Corporation, Danaher Corporation, Genscript Biotech Corporation, Lonza Group AG, Merck KGaA Inc., Oxford Biomedica plc, Sartorius AG, Takara Bio Inc., Thermo Fisher Scientific Inc., Wuxi AppTec, Acuitas Therapeutics, Evonik Industries AG, Exelead, Inc., Entos Pharmaceuticals, Genevant Sciences GmbH, T&T Scientific Corporation, Moderna, Inc., CureVac N.V.
Factors driving the growth of the viral and non-viral vector manufacturing market are rapid uptake of viral vectors to develop innovative therapies, increasing number of clinical studies for the development of gene therapy, favorable funding scenario for vector-based therapies, increasing adoption of nucleic acid therapeutics, and rise in synergistic activities in the market.
Some of the main challenges restricting the growth of the viral and non-viral vector manufacturing market are the unaffordable cost of gene therapy, the high manufacturing cost of viral vectors, complications associated with large-scale production of viral vectors, and low transfection efficiency.
The potential opportunities that are likely to boost the growth of the viral and non-viral vector manufacturing market are the rise in demand for synthetic genes, and the emergence of next-generation vectors, limitation of viral vectors.
Similar Product

You may also like

Published Year: 2021

Global Cell and Gene Therapy Market: Focus on Product Type, Therapeutic Class, Pipeline, Regional an

The global cell and gene therapy market was valued at $2,599.7 million in 2020, and it is ...